The Edwards Lifesciences Triformis Resilia is the first dedicated surgical tricuspid valve on the market cleared with data from off-label use of mitral valves.
Robert Hawkins, MD, discussed an updated risk calculator—and the latest data on SAVR after TAVR—for a new video interview with Cardiovascular Business.
Follow-up care after a successful heart transplant can be challenging—both for providers and their patients. Consider, for example, the fact that so many patients who develop complications never actually present with symptoms.